Who won: Blood Group Genotyping for Sickle Cell and Thalassaemia

About this contract

Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping. Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026.

Who won contracts like this

• ✓Answer against the marking scheme, not the question text — NHS England scores each response, so map your evidence to the published criteria and weightings.
• ✓Lead with evidenced capability and social value — for public sector work these usually outweigh price.
• ✓Show recent, comparable delivery: name similar public sector contracts you've delivered for public bodies, with measurable outcomes.
• ✓This one's been awarded — but NHS England retenders on a cycle. Get matched the day the next one lands and start your draft early.

BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.

Related resources

Similar contracts